Signaling pathways and therapeutic approaches in glioblastoma multiforme
M Khabibov, A Garifullin… - International …, 2022 - spandidos-publications.com
Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …
associated with a poor clinical prognosis. Despite the progress in the understanding of the …
[HTML][HTML] Major features of the 2021 WHO classification of CNS tumors
HL Smith, N Wadhwani, C Horbinski - Neurotherapeutics, 2022 - Elsevier
Advances in the understanding of the molecular biology of central nervous system (CNS)
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …
[HTML][HTML] PDGF signaling inhibits mitophagy in glioblastoma stem cells through N6-methyladenosine
Dysregulated growth factor receptor pathways, RNA modifications, and metabolism each
promote tumor heterogeneity. Here, we demonstrate that platelet-derived growth factor …
promote tumor heterogeneity. Here, we demonstrate that platelet-derived growth factor …
EGFR, the Lazarus target for precision oncology in glioblastoma
B Lin, J Ziebro, E Smithberger, KR Skinner… - Neuro …, 2022 - academic.oup.com
The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …
Review on NAD (P) H dehydrogenase quinone 1 (NQO1) pathway
NQO1 is an enzyme present in humans which is encoded by NQO1 gene. It is a protective
antioxidant agent, versatile cytoprotective agent and regulates the oxidative stresses of …
antioxidant agent, versatile cytoprotective agent and regulates the oxidative stresses of …
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major
hurdle to effective treatment. Evidence indicates a key role for oncogene amplification on …
hurdle to effective treatment. Evidence indicates a key role for oncogene amplification on …
Extracellular vesicles derived from glioblastoma promote proliferation and migration of neural progenitor cells via PI3K-Akt pathway
J Pan, S Sheng, L Ye, X Xu, Y Ma, X Feng, L Qiu… - Cell Communication and …, 2022 - Springer
Background Glioblastomas are lethal brain tumors under the current combinatorial
therapeutic strategy that includes surgery, chemo-and radio-therapies. Extensive changes in …
therapeutic strategy that includes surgery, chemo-and radio-therapies. Extensive changes in …
Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors
F Fabro, MLM Lamfers, S Leenstra - Cancers, 2022 - mdpi.com
Simple Summary Drug resistance is a major issue in brain tumor therapy. Despite novel
promising therapeutic approaches, glioblastoma (GBM) remains refractory in showing …
promising therapeutic approaches, glioblastoma (GBM) remains refractory in showing …
Guilt by association: EcDNA as a mobile transactivator in cancer
Extrachromosomal DNA (ecDNA), first described in the 1960s, is emerging as a prevalent
but poorly characterized oncogenic alteration in cancer. ecDNA is a reservoir for oncogene …
but poorly characterized oncogenic alteration in cancer. ecDNA is a reservoir for oncogene …
Epidermal growth factor receptor kinase inhibitor ameliorates β-amyloid oligomer-induced alzheimer disease in Swiss albino mice
J Dhamodharan, G Sekhar, A Muthuraman - Molecules, 2022 - mdpi.com
Alzheimer's disease (AD) is one of the major neurodegenerative disorders, and its incidence
increases globally every year. Currently, available AD drugs symptomatically treat AD with …
increases globally every year. Currently, available AD drugs symptomatically treat AD with …